Related references
Note: Only part of the references are listed.EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB
Kailong Lin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Cancer Statistics, 2015
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors
Noemi Reguart et al.
FUTURE ONCOLOGY (2015)
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Scott N. Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Non-Small Cell Lung Cancer, Version 6.2015 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2015)
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Nan Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
Yanna Tang et al.
ONCOTARGET (2015)
Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma
Weiqing Jing et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
A. D'Incecco et al.
BRITISH JOURNAL OF CANCER (2015)
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall- cell lung cancer
K. Azuma et al.
ANNALS OF ONCOLOGY (2014)
Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)
J. R. Brahmer et al.
EUROPEAN JOURNAL OF CANCER (2014)
Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients
Tanusree Paul et al.
EUROPEAN JOURNAL OF CANCER (2014)
Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes
Naoko Okiyama et al.
JOURNAL OF AUTOIMMUNITY (2014)
The effect of resveratrol and its methylthio-derivatives on EGFR and Stat3 activation in human HaCaT and A431 cells
Michal Cichocki et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy
T. Kumai et al.
BRITISH JOURNAL OF CANCER (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay et al.
CANCER DISCOVERY (2013)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
Ramaswamy Govindan et al.
CELL (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes
Brian P. Pollack et al.
CLINICAL CANCER RESEARCH (2011)
CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression
Xueqing Sun et al.
CANCER AND METASTASIS REVIEWS (2010)
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib
Emma Guttman-Yassky et al.
EUROPEAN JOURNAL OF CANCER (2010)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Keratinocyte-Associated B7-H1 Directly Regulates Cutaneous Effector CD8+ T Cell Responses
Patcharee Ritprajak et al.
JOURNAL OF IMMUNOLOGY (2010)
EGFR Regulates the Expression of Keratinocyte-Derived Granulocyte/Macrophage Colony-Stimulating Factor In Vitro and In Vivo
Francesca Mascia et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Keratinocytes Function as Accessory Cells for Presentation of Endogenous Antigen Expressed in the Epidermis
Brian S. Kim et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Skin toxicities associated with epidermal growth factor receptor inhibitors
Tianhong Li et al.
TARGETED ONCOLOGY (2009)
The epidermal growth factor receptor system in skin repair and inflammation
Saveria Pastore et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies
Bret Wacker et al.
CLINICAL CANCER RESEARCH (2007)
Stimulation of purinergic receptors modulates chemokine expression in human keratinocytes
Saveria Pastore et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)
Expression of CD1d molecules by human Schwann cells and potential interactions with immunoregulatory invariant NK T cells
Jin S. Im et al.
JOURNAL OF IMMUNOLOGY (2006)
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21
Gary M. Clark et al.
CLINICAL LUNG CANCER (2006)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The expression of B7-H1 on keratinocytes in chronic inflammatory mucocutaneous disease and its regulatory role
P Youngnak-Piboonratanakit et al.
IMMUNOLOGY LETTERS (2004)
Complex regulation of signal transducers and activators of transcription 3 activation in normal and malignant keratinocytes
MRD Quadros et al.
CANCER RESEARCH (2004)
Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation
F Mascia et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Share Paper
